- Q4 2023 PDS Biotechnology Corp Earnings Call TranscriptMar 27, 2024€4.13 (-4.95%)Earnings
- Q3 2023 PDS Biotechnology Corp Earnings Call TranscriptNov 14, 2023€4.85 (+7.55%)Earnings
- PDS Biotechnology Corp To Host Key Opinion Leader Roundtable TranscriptOct 03, 2023
- PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Q2 2023 PDS Biotechnology Corp Earnings Call TranscriptAug 14, 2023€4.37 (-0.11%)Earnings
- PDS Biotechnology Corp To Host Post ASCO Call TranscriptJun 06, 2023
- Q1 2023 PDS Biotechnology Corp Earnings Call TranscriptMay 15, 2023€5.86 (-0.34%)Earnings
- PDS Biotechnology Corp To Host Key Opinion Leader Call TranscriptApr 21, 2023
- Q4 2022 PDS Biotechnology Corp Earnings Call TranscriptMar 28, 2023€5.37 (+0.75%)Earnings
- PDS Biotechnology Corp at Noble Capital Markets Takeaway Series on Channelchek- J.P. Morgan Healthcare Conference TranscriptJan 26, 2023
- PDS Biotechnology Corp Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine TranscriptJan 03, 2023
- Q3 2022 PDS Biotechnology Corp Earnings Call TranscriptNov 14, 2022€5.37 (-1.29%)Earnings
- PDS Biotechnology Corp Head And Neck Cancer KOL Roundtable TranscriptOct 26, 2022
- PDS Biotechnology Corp Update Call TranscriptAug 25, 2022
- Q2 2022 PDS Biotechnology Corp Earnings Call TranscriptAug 08, 2022€5.16 (+1.38%)Earnings
- PDS Biotechnology Corp Post ASCO Call TranscriptJun 07, 2022
- Q1 2022 PDS Biotechnology Corp Earnings Call TranscriptMay 11, 2022€4.18 (-1.90%)Earnings
- Q4 2021 PDS Biotechnology Corp Earnings Call TranscriptMar 31, 2022Earnings
- PDS Biotechnology Corp Extraordinary Shareholders Meeting TranscriptJan 19, 2022
- Q3 2021 PDS Biotechnology Corp Earnings Call TranscriptNov 10, 2021€8.84 (-4.93%)Earnings
- Q2 2021 PDS Biotechnology Corp Earnings Call TranscriptAug 12, 2021€8.93 (-2.75%)Earnings
- PDS Biotechnology Corp Oncology R&D Day TranscriptJun 16, 2021
- PDS Biotechnology Post-ASCO Conference Call - Corporate Analyst Meeting TranscriptJun 08, 2021
- Q1 2021 PDS Biotechnology Corp Earnings Call TranscriptMay 13, 2021€3.61 (+0.47%)Earnings
- Q2 2020 PDS Biotechnology Corp Earnings Call TranscriptAug 13, 2020€2.38 (-1.65%)Earnings
PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference Transcript
So good afternoon. My name is Wayne Wu and I am the associate on Louise Chen's Large Cap Pharma, BioPharma & Biotech team here at Cantor. Thank you so much for joining us today with our panel presentation with PDS Biotechnology as well as Immutep. We're thrilled to have Frank as well as Marc to give us their wonderful presentations. So let's start with Frank. Thank you.
Thank you very much for the introduction. Let's see. How do I move this forward? Okay. Okay. So I'm just before I start, I'd just like please to advise everyone to get comfortable and be familiar with the risk factors associated with PDS and as filed with the SEC.
So who is PDS Biotechnology? We are a mid to late clinical stage biotech company developing immunotherapies that train and activate the immune system to specifically target cancer. We are developing targeted immunotherapies based on the company's proprietary, Versamune T-cell activating technology platform.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)